Clinical Outcomes and Prognostic Factors in Driver-Negative Stage IV Non-small Cell Lung Cancer Patients Receiving Thoracic Radiotherapy: A Single-Center Retrospective Study.
Abstract
IntroductionThe role of thoracic radiotherapy (TRT) in stage IV non-small cell lung cancer (NSCLC) without targetable driver alterations remains unclear. We evaluated outcomes, prognostic factors, and safety in patients receiving TRT and systemic therapy.MethodsIn this single-center retrospective cohort study, we analyzed patients identified according to predefined criteria who received TRT and systemic therapy at a single tertiary cancer center between January 2019 and December 2023. Overall survival (OS), progression-free survival (PFS), and local control (LC) were estimated using Kaplan-Meier analysis. Conventional Cox regression constituted the primary prognostic analysis, with Firth penalized Cox regression used as a small-sample sensitivity analysis. Exploratory conditional landmark and time-dependent Cox analyses assessed potential time-related bias.ResultsForty-eight patients were included. Median OS, PFS, and LC were 33.17 months (95% CI 19.29-47.05), 12.17 months (95% CI 8.89-15.45), and 12.47 months (95% CI 9.00-15.98), respectively. Best in-field response was partial response in 12 patients (25.0%), stable disease in 32 (66.7%), and progressive disease in 4 (8.3%). Squamous histology was consistently associated with poorer OS and PFS, whereas other multivariable associations were less stable in sensitivity analyses. Time-dependent anti-PD-1 exposure was not significantly associated with OS. Metastatic progression predominated among patients who died. In the exploratory 6-month conditional landmark analysis, TRT timing was not associated with OS or PFS. Grade 3-4 pneumonitis and esophagitis each occurred in one patient (2.1%), and no grade 5 adverse event was documented.ConclusionMost irradiated thoracic lesions showed partial response or stable disease at the best post-TRT assessment, while distant progression predominated among patients who died during follow-up. The prognostic findings are exploratory and require validation in larger prospective cohorts.